The FDA has approved J&J's (JNJ) Invokana drug for treating type 2 diabetes in a new way by...
The FDA has approved J&J's (JNJ) Invokana drug for treating type 2 diabetes in a new way by causing the body to excrete blood sugar via the urine rather than affecting the supply or use of insulin. The agency said J&J must carry out five post-marketing studies to determine whether the drug increases the risks of strokes, heart attacks and other side effects. Invokana is forecast to generate sales of $667M by 2016.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Feb 23, 2015)
at Nasdaq.com (Feb 19, 2015)
at Nasdaq.com (Feb 17, 2015)
at Nasdaq.com (Feb 10, 2015)
at Investor's Business Daily (Jan 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs